National Cancer Institute
In 2015, the National Cancer Institute (NCI) gave The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James) a perfect score of 10 and the NCI’s highest descriptor, “exceptional,” following a site review that resulted in Ohio State’s re-designation as a comprehensive cancer center—a designation the university has competitively maintained since 1976. It was the second consecutive time in 10 years that the OSUCCC – James has earned the NCI’s “exceptional” rating, having also done so in 2010. With this re-designation, the OSUCCC – James retains its status as one of only 46 CCCs in the nation, an honor accompanied by another five years of NCI multimillion dollar core grant funding support for scientific leadership and administration, shared technology and services, and development.
National Cancer Institute's National Clinical Trials Network
The OSUCCC – James is a member of the National Cancer Institute's (NCI) National Clinical Trials Network (NCTN) as a Lead Academic Participating Site (LAPS). The OSUCCC – James is one of 30 academic research institutions that has demonstrated the ability to enroll a high number of patients onto NCTN trials while providing scientific leadership in the design and conduct of clinical trials.
The James in September 2013 achieved the highly prestigious Magnet® designation from the American Nurses Credentialing Center (ANCC). The Magnet Recognition Program® recognizes healthcare organizations for quality patient care, nursing excellence and innovations in professional nursing practice.
The Joint Commission
The James Cancer Hospital and Solove Research Institute is accredited by The Joint Commission, an independent, not-for-profit organization that evaluates the quality and safety of care provided by healthcare organizations across the nation. The James’ most recent Joint Commission survey was in July 2014.
National Comprehensive Cancer Network
The James is a charter member of the National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 27 of the world’s leading cancer centers devoted to patient care, research and education. The NCCN is dedicated to improving the quality, effectiveness and efficiency of cancer care so patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, the NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system.
CEO Cancer Gold Standard
The Ohio State University Wexner Medical Center has earned CEO Cancer Gold Standard™ reaccreditation for maintaining a strong commitment to the health of its employees and satisfying the latest comprehensive requirements of the Gold Standard. The CEO Roundtable on Cancer, a nonprofit organization of CEOs that was founded by former President George H.W. Bush, developed and administers the Gold Standard, an employee wellness accreditation program that addresses cancer in the workplace. To earn and maintain the CEO Cancer Gold Standard™ , an employer must meet requirements in corporate culture and health benefits, such as prohibiting tobacco use and supporting tobacco-cessation efforts; promoting physical activity, nutrition and weight management; and providing health insurance options that include detecting cancer early. The Ohio State Wexner Medical Center first earned the CEO Cancer Gold Standard™ in 2012. Health care at Ohio State consists of six hospitals, including the Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute.
The American College of Surgeons Commission on Cancer
The James Cancer Hospital and Solove Research Institute is accredited by the American College of Surgeons Commission on Cancer (CoC). The CoC accredits cancer programs based on a comprehensive evaluation of institutional and programmatic resources; program management and administration; clinical management; inpatient and outpatient care; supportive care services; research; quality management and improvement; cancer-data management; public education; prevention and detection; and professional education and staff support.
Foundation for the Accreditation of Cellular Therapy
The James’ blood and marrow transplant (BMT) program is accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) for allogeneic and autologous transplantation, including clinical, collection (apheresis and perioperative services for bone marrow harvest) and processing. FACT accreditation attests to the high quality of the OSUCCC – James’ BMT program.
National Accreditation Program for Breast Centers
The Stefanie Spielman Comprehensive Breast Center is accredited by the National Accreditation Program for Breast Centers (NAPBC). A coalition of professional organizations, the NAPBC works to provide the most efficient and contemporary breast care using scientific evidence about what works best for patients. The NAPBC monitors compliance to its standards at each accredited breast center. The NAPBC Board is composed of leadership from many medical disciplines and upholds nationally recognized quality performance measures for breast cancer treatment. It is administered by the American College of Surgeons (ACS), which for more than 100 years has led national and international initiatives to improve quality in hospitals.
Breast Imaging Center of Excellence
The OSUCCC – James is designated a Breast Imaging Center of Excellence (BICOE) by the American College of Radiology (ACR). The BICOE designation is awarded to breast imaging centers that achieve excellence by seeking and earning accreditation in all of the ACR’s voluntary breast imaging accreditation programs and modules, in addition to the mandatory Mammography Accreditation Program.
Commission on Accreditation of Rehabilitation Facilities (CARF) International
The Ohio State University Wexner Medical Center’s Dodd Hall Inpatient Rehabilitation Hospital is among the first in the world to be accredited as a “Cancer Rehabilitation Specialty Program” by the Commission on Accreditation of Rehabilitation Facilities (CARF) International, an independent, nonprofit accreditor of health and human services, including medical rehabilitation. Ohio State’s Wexner Medical Center’s Dodd Hall Inpatient Rehabilitation Hospital is the first in Ohio, the second in the country and the third in the world to receive this new ‘gold standard’ accreditation for oncology rehabilitation services. Rehabilitation services available for cancer patients include physical, occupational, speech and recreation therapy, along with complementary and alternative therapies such as music and art therapy and aromatherapy. In addition, patients and families are encouraged to attend educational classes designed to help them adjust to life after a cancer diagnosis.
OncLive: Strategic Alliance Partnership
The OSUCCC – James has a Strategic Alliance Partnership with OncLive, the official Website for the Oncology Specialty Group. This partnership will provide news and updates from the OSUCCC – James to the oncology community. OncLive publishes Oncology & Biotech News, OncologyLive, Urologists in Cancer Care, Oncology Nursing News, and Contemporary Oncology. The mission of OncLive and these publications is to provide oncology professionals with the resources and information they need to provide the best patient care.
National Pancreas Foundation Center
Ohio State’s multidisciplinary pancreas program — which treats both cancerous and non-cancerous conditions of the pancreas — has been designated as a National Pancreas Foundation (NPF) Center, one of 30 hospitals nationwide and the only adult hospital in Ohio to earn this distinction. NPF Centers must pass a rigorous review to demonstrate the hospital’s focus on multidisciplinary treatment of pancreatitis and pancreatic cancer, with an emphasis on providing the best possible outcomes and quality of life considerations. Criteria include: having the required physician specialties such as gastroenterologists, pancreas surgeons, interventional radiologists and a gastrointestinal pathologist; patient support services such as pain management, nutrition and psychosocial support; and access to innovative clinical trials.
Designated Centre of Integrated Oncology and Palliative Care
The James Cancer Hospital and Solove Research Institute is among 14 institutions around the world that were named as Designated Centres of Integrated Oncology and Palliative Care by the European Society for Medical Oncology (ESMO) at the ESMO 2016 Congress in Copenhagen, Denmark. The Designated Centre distinction is now held by 200 institutions in 42 countries.
The ESMO Designated Centres Program is the premier initiative worldwide for championing integrated programs in oncology and palliative care to ease the physical and mental suffering of cancer patients during treatment and at the end of life. Since 2003 the distinction has recognized cancer centers that achieve a high standard of integration of medical oncology and palliative care. The distinction is valid for three years. Survey results reported at the ESMO 2016 Congress indicate that seven of 10 patients with advanced cancer receive a palliative care consultation at ESMO Designated Centres.
National Institutes of Health
The National Institutes of Health (NIH) has awarded a $25.4 million grant to The Ohio State University Center for Clinical and Translational Science (CCTS), a collaboration between the University and Nationwide Children’s Hospital (NCH) to accelerate basic science discoveries into life-saving medical advances. The CCTS received its initial Clinical and Translational Science Award (CTSA) from the NIH in 2008. Since then, the Center has helped connect hundreds of researchers across Ohio with the resources needed to discover techniques and treatments for such diseases as obesity, diabetes, heart disease, cancer and Alzheimer’s, as well as childhood illnesses such as muscular dystrophy. The CCTS is directed by Rebecca Jackson, MD, associate dean for clinical research in Ohio State’s College of Medicine and a member of Ohio State’s Comprehensive Cancer Center.
In 2013, The Ohio State University received an $18.7 million federal grant to establish a research center for studying tobacco-use patterns, nicotine dependence and cancer biomarkers, industry marketing practices and public perceptions that will help the U.S. Food and Drug Administration put science behind its new role in regulating tobacco. Ohio State’s center is one of 14 established nationally by this initiative, called the Tobacco Centers of Regulatory Science Program. The National Cancer Institute administers the Ohio state funding. The center is co-led by OSUCCC Deputy Director Peter Shields, MD, and Mary Ellen Wewers, PhD, MPH, RN, a professor in the College of Public Health.
The OSUCCC – James has been awarded and holds three separate grant contracts with the National Cancer Institute (NCI) totaling millions of dollars for NCI-related collaborative work designed to improve clinical care and patient outcomes across the country. These include:
- A five-year, $7.3 million grant awarded in 2014 establishing Ohio State as an NCI National Clinical Trials Network (NCTN) Lead Academic Participating Site. Richard Goldberg, MD, physician-in-chief at the OSUCCC – James, is principal investigator (PI). The NCTN develops and conducts state-of-the-art cancer treatment and advanced imaging clinical trials, especially large multi-institutional trials evaluating new cancer therapies and related clinical approaches for adult and pediatric patients. The grant supports OSUCCC – James participation in the NCI-funded clinical oncology cooperative groups.
- A five-year, $4.19 million grant awarded in 2014 (renewing a previous NCI phase I grant contract) for conducting phase I clinical trials on novel anticancer agents (new drugs and drug combinations) as part of an NCI Experimental Therapeutics-Clinical Trials Network (ET-CTN) that supports the NCTN. Michael Grever, MD, professor and chair of the Department of Internal Medicine at Ohio State and co-leader of the Leukemia Research Program at the OSUCCC – James, is PI for the grant. The OSUCCC – James works with other network members to define the drug development plan and conduct clinical trials for these novel anticancer agents. A grant awarded in 2011 that could be worth more than $8 million over five years if fulfilled to capacity for conducting phase II clinical trials to test novel anticancer agents in new indications. Miguel Villalona, MD, professor and director of the Division of Medical Oncology at Ohio State and a member of the Translational Therapeutics Program at the OSUCCC – James, is PI for the grant, which enables the OSUCCC – James to conduct phase II studies as the lead institution in a consortium that includes three other cancer centers as collaborators.
U.S. News & World Report
Ohio State's Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute stands out once again for cancer care in the U.S. News & World Report "America's Best Hospitals" issue, ranking among the top cancer programs in the country. The "America's Best Hospitals" issue, considered by many consumers and health care industry analysts as a leading indicator of quality care and performance, is compiled using data collected annually.
Becker's Hospital Review
Becker's Hospital Review includes The James on its list of 100 Hospitals and Health Systems With Great Oncology Programs. The Becker’s website states that these hospitals are leading the way in quality patient care, cancer outcomes and research, and have been recognized for excellence in this specialty by such reputable healthcare rating resources as U.S. News & World Report, Thomson Reuters, the National Cancer Institute, the American College of Surgeons, the American Nurses Credentialing Center and CareChex. Each organization has demonstrated a focus on patient-centered cancer care and emphasis on continual innovation in treatments and services.
Institute for Diversity in Health Management
The Institute for Diversity in Health Management, an American Hospital Association (AHA) affiliate, has recognized Ohio State’s Wexner Medical Center as a “Best in Class” hospital as part of “Diversity and Disparities: A Benchmarking Study of U.S. Hospitals.” The Institute commissioned the Health Research & Educational Trust to conduct a national survey of hospitals to examine the actions they are taking to address health disparities and improve diversity. Ohio State was chosen out of more than 1,100 hospitals that responded to the survey.
University HealthSystem Consortium
The Ohio State University Wexner Medical Center is one of 10 academic medical centers in the nation delivering the highest quality of care based on results of a study commissioned by the University HealthSystem Consortium (UHC). In recognition, the Wexner Medical Center received the 2011 UHC Quality Leadership Award, which is given to academic medical centers that demonstrate excellence in delivering high-quality care as measured by a Quality & Accountability Study that UHC commissions annually.
Other Accolades & Achievements
- The OSUCCC – James is one of only a few comprehensive cancer centers funded by the National Cancer Institute (NCI) to conduct both phase I and phase II clinical trials on novel anticancer drugs.
- Charter membership in the National Comprehensive Cancer Network, an alliance of 21 leading cancer centers that establishes national clinical oncology practice guidelines and standards of cancer care.
- The James Cancer Hospital and Solove Research Institute is one of 11 freestanding cancer hospitals in the nation that constitute the Alliance of Dedicated Cancer Centers.
- A record of consistently recruiting the world’s leading cancer researchers, whose groundbreaking work has helped Ohio State’s NCI grant funding quadruple over the past decade.
- A robust clinical trials program that involves the participation of nearly 1 in 3 patients diagnosed and treated at the OSUCCC – James and includes an online cancer clinical trials search tool.
- The Total Cancer Care® Program, a medical information and biorepository research protocol that involves an innovative lifetime partnership with patients through universal consenting.
- A set of 21 shared resources that provide investigators with ready access to specialized technologies, services, methodologies and consultations that enhance their ability to conduct cancer research.
- A unique Drug Development Institute that was created to accelerate cancer drug discovery and development at Ohio State through collaboration and results-based project management to speed new cancer treatments to patients.